Precigen (PGEN) Non Operating Investment Income (2012 - 2025)
Precigen (PGEN) posted quarterly Non Operating Investment Income of -$111.5 million for Q3 2025, down 2600.04% quarter-over-quarter from $4.5 million in Q2 2025.
Powered by 
Analysis
Precigen (PGEN) Non Operating Investment Income (2012 - 2025) Analysis & Trends
Precigen (PGEN) has reported Non Operating Investment Income for 5 consecutive years, with -$111.5 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Non Operating Investment Income changed N/A year-over-year to -$111.5 million; the TTM figure through Mar 2026 stood at -$107.0 million (down 229.55% YoY), while the FY2025 annual figure was -$139.5 million, changed N/A from the prior year.
- Non Operating Investment Income eased to -$111.5 million in Q3 2025 per PGEN's latest filing, from $4.5 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $4.5 million in Q2 2025 and bottomed at -$111.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Precigen | 2.53 Bn | 2.53 Bn | 52.17 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2025 | -111.50 Mn |
| Jun 30, 2025 | 4.46 Mn |
| Mar 31, 2025 | -32.48 Mn |
| Mar 31, 2016 | -22.33 Mn |
| Mar 31, 2015 | 115.45 Mn |
| Mar 31, 2013 | 7.42 Mn |
| Dec 31, 2012 | -7.40 Mn |